161 related articles for article (PubMed ID: 28110366)
1. Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology.
Gayleard JL; Mychailyszyn MP
Atten Defic Hyperact Disord; 2017 Sep; 9(3):149-160. PubMed ID: 28110366
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
3. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
[TBL] [Abstract][Full Text] [Related]
4. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
[TBL] [Abstract][Full Text] [Related]
5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
[TBL] [Abstract][Full Text] [Related]
7. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): A meta-analysis of controlled trials.
Ravishankar V; Chowdappa SV; Benegal V; Muralidharan K
Asian J Psychiatr; 2016 Dec; 24():53-58. PubMed ID: 27931908
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder.
Khoodoruth MAS; Ouanes S; Khan YS
Res Dev Disabil; 2022 Sep; 128():104275. PubMed ID: 35691145
[TBL] [Abstract][Full Text] [Related]
12. Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.
Griffiths KR; Leikauf JE; Tsang TW; Clarke S; Hermens DF; Efron D; Williams LM; Kohn MR
J Psychiatr Res; 2018 Jul; 102():57-64. PubMed ID: 29674270
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
Ercan ES; Akyol Ardic U; Kabukcu Basay B; Ercan E; Basay O
Atten Defic Hyperact Disord; 2013 Dec; 5(4):377-85. PubMed ID: 23737214
[TBL] [Abstract][Full Text] [Related]
14. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
[TBL] [Abstract][Full Text] [Related]
15. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
Holzer B; Lopes V; Lehman R
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
[TBL] [Abstract][Full Text] [Related]
17. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
Tanaka Y; Rohde LA; Jin L; Feldman PD; Upadhyaya HP
J Child Adolesc Psychopharmacol; 2013 May; 23(4):262-70. PubMed ID: 23683141
[TBL] [Abstract][Full Text] [Related]
20. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
